When comparing the novel NKG2D/2B4/CD3ζ CAR-NK cells to T cells transduced with the CD28/4-1BB/CD3ζ CAR, both demonstrated very similar anti-tumor activity, fortifying the importance of vehicle-specific CAR design. This evidence concerns the gene CD28 and neoplasm.